Presbyopia Pipeline Analysis & Clinical Trials Assessment, 2025, Delveinsight Visus Therapeutics, Glaukos Corporation, Cellix Bio, Orasis Pharmaceuticals, Cellix Bio

(MENAFN- GetNews)


"Presbyopia Pipeline Analysis & Clinical Trials Assessment"DelveInsight's,“Presbyopia - Pipeline Insight, 2025” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Presbyopia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

DelveInsight reports that over 10 key companies are actively engaged in developing more than 10 therapies for the treatment of Presbyopia.

Presbyopia Overview:

Presbyopia is an age-related vision disorder in which the eye's lens gradually loses its ability to focus on nearby objects. It is the most common physiological change observed in adults and typically manifests as difficulty with near vision. Individuals with presbyopia often report eye strain, headaches, and the need to hold reading material farther away to see it clearly, with reading glasses being the most common corrective solution.

While presbyopia is widely recognized, its prevalence in low- and middle-income countries is less well-documented, as most regional studies have concentrated on distance vision errors. The exact cause remains debated, though the most accepted theory attributes it to increasing stiffness of the crystalline lens, which reduces accommodative ability.

Symptoms usually become noticeable around the age of 40, when patients struggle to read at a normal distance but may find it easier if the text is held farther away. In early stages, headaches are frequent, and individuals with heavy screen use may experience symptoms earlier due to latent accommodative dysfunction.

Download our report @

"Presbyopia Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Presbyopia Therapeutics Market.

Key Takeaways from the Presbyopia Pipeline Report

• DelveInsight's Presbyopia pipeline report highlights a dynamic landscape, with over 10 active companies developing more than 10 potential therapies for Presbyopia treatment.

• LENZ Therapeutics has submitted a New Drug Application (NDA) for LNZ100, a preservative-free, single-use, once-daily eye drop containing aceclidine. The FDA has set a PDUFA target action date of August 8, 2025. LNZ100 is designed to provide a pupil-selective, long-acting treatment option for presbyopia.

• Orasis Pharmaceuticals received FDA approval for Qlosi in October 2023. This low-dose, preservative-free eye drop can be used up to twice daily, with effects lasting up to 8 hours, offering a gentler alternative with potentially fewer side effects compared to higher-dose therapies.

• Key companies in the Presbyopia space include Visus Therapeutics, Glaukos Corporation, Cellix Bio, Orasis Pharmaceuticals, and others, all working to expand treatment options.

• Promising therapies in development include LNZ100, GLK-302, among others.

Presbyopia Pipeline Analysis

The Presbyopia pipeline insights report 2025, provides insights into:

• Provides comprehensive insights into key companies developing therapies in the Presbyopia Market.

• Categorizes Presbyopia therapeutic companies by development stage: early, mid, and late-stage.

• Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

• Reviews emerging Presbyopia drugs under development based on:

  • Stage of development

  • Presbyopia Route of administration

  • Target receptor

  • Monotherapy vs. combination therapy

  • Presbyopia Mechanism of action

  • Molecular type

• Offers detailed analysis of:

  • Company-to-company and company-academia collaborations

  • Presbyopia Licensing agreements

  • Funding and investment activities supporting future Presbyopia market advancement.

Request for a sample report @

Presbyopia Emerging Drugs

• LNZ100: Lenz Therapeutics

LNZ100 is a preservative-free, single-use, once-daily eye drop that contains aceclidine, a selective muscarinic receptor agonist that enhances near vision by constricting the pupil. Unlike other similar therapies, aceclidine's distinct mechanism separates the miotic effect from ciliary muscle stimulation, reducing the risk of myopic shift and brow ache. This makes LNZ100 a long-lasting and effective treatment for presbyopia, the age-related condition characterized by gradual decline in near vision due to lens stiffening. The FDA has accepted the New Drug Application (NDA) for LNZ100, and it is currently in the registration phase of clinical development for presbyopia.

• GLK-302: Glaukos Corporation

Glaukos Corporation is developing GLK-302, a sterile ophthalmic cream containing pilocarpine for the treatment of presbyopia. When applied to the eyelid, the cream delivers pilocarpine transdermally to the eye, where it constricts the pupil and enhances near vision by increasing depth of focus without notably affecting distance vision. GLK-302 is currently in Phase II clinical trials for presbyopia.

Presbyopia Companies

More than 10 key companies are actively developing therapies for presbyopia, with Lenz Therapeutics leading the field as its drug candidates have reached the most advanced Phase III stage.

DelveInsight's report covers around 10+ products under different phases of Presbyopia clinical trials like

• Presbyopia Late stage Therapies (Phase III)

• Presbyopia Mid-stage Therapies (Phase II)

• Presbyopia Early-stage Therapies (Phase I)

• Presbyopia Pre-clinical and Presbyopia Discovery stage Therapies

• Presbyopia Discontinued & Inactive Therapies

Presbyopia pipeline report provides the Presbyopia therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Presbyopia Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Presbyopia Therapies and Key Presbyopia Companies: Presbyopia Clinical Trials and recent advancements

Presbyopia Pipeline Therapeutic Assessment

. Presbyopia Assessment by Product Type

. Presbyopia By Stage

. Presbyopia Assessment by Route of Administration

. Presbyopia Assessment by Molecule Type

Download Presbyopia Sample report to know in detail about the Presbyopia treatment market @ Presbyopia Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Presbyopia Current Treatment Patterns

4. Presbyopia - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Presbyopia Late-Stage Products (Phase-III)

7. Presbyopia Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Presbyopia Discontinued Products

13. Presbyopia Product Profiles

14. Presbyopia Key Companies

15. Presbyopia Key Products

16. Dormant and Discontinued Products

17. Presbyopia Unmet Needs

18. Presbyopia Future Perspectives

19. Presbyopia Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Presbyopia Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

MENAFN08092025003238003268ID1110033989